Futura Medical appoints Roy Davis as non-executive director

2024-01-09

高管变更并购

Futura Medical the pharmaceutical company developing innovative sexual health products, has announced the appointment of Roy Davis as a non-executive director with immediate effect. Davis brings a wealth of commercial experience in medical devices companies and has a proven track record of successfully scaling companies and delivering substantial value for shareholders. He has held leadership positions at a number of publicly quoted medtech companies, including CEO of Optos, a retinal imaging device manufacturer, from 2008 to 2016 until its sale to Nikon for £259m in February 2015. From 2007 to 2008, Davis was CEO of Gyrus Group, a specialist in minimally invasive surgery and visualisation, until its acquisition by Olympus Corporation in 2008 for $1.9 billion. He is currently non-executive chair at LungLife AI, Foster and Freeman and Rair Health and was until recently, non-executive chair at Medica Group until its acquisition by IK Partners for £269 million earlier this year. On 7th December, it was announced that Davis will become a non-executive director and chair designate of Inspiration Healthcare Group with effect from 25th January 2024. Jeff Needham, chairman of Futura Medical said: “Roy brings with him significant commercial expertise and a proven track record of creating substantial shareholder value. His appointment will add to the depth and breadth of experience of the Futura Board as we continue to monetise our key asset, Eroxon, move towards profitability, and deliver on our strategy.” Roy Davis, said: “I am delighted to be joining the Board of Futura. The Company is providing novel solutions in the sexual health sector and has exciting opportunities ahead of it. I look forward to working with the Board and Executive Team to help execute the strategy and deliver shareholder value.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构